Bond DA, Switchenko JM, Villa D, et al. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2021;5(23):5179-5189.

doi:10.1182/bloodadvances.2025018576

In “Acknowledgments” on page 5187, there should be a statement that author Christopher R. Flowers received support from the Cancer Prevention and Research Institute of Texas (grant RR190079), where he is a Cancer Prevention and Research Institute of Texas Scholar in Cancer Research.

2025

Bond DA, Switchenko JM, Villa D, et al. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2021;5(23):5179-5189.

Cited By

Email alerts

ASH Publications

American Society of Hematology

Bond DA, Switchenko JM, Villa D, et al. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2021;5(23):5179-5189. Open Access

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Bond DA, Switchenko JM, Villa D, et al. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2021;5(23):5179-5189.